BMRN

Biomarin Pharmaceutical INC

-$839.9M

Net Activity

Institutions Holding

554

Popularity Rank

#979

Avg Weight

0.21%

Total Value

$10.5B

Ownership Trend

554 institutions currently hold BMRN, with 286 net buyers and 237 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Neutral

Based on recent trading activity

Net Selling Institutions

237

Net Buying Institutions

286

Key Holders

Key Holders

Top 5 by Value

BI
BlackRock, Inc.
$1.1B
D&
Dodge & Cox
$822.6M
PM
Primecap Management Co/ca/
$801.8M
VC
Vanguard Capital Management LLC
$488.3M
VP
Vanguard Portfolio Management LLC
$468.8M

Top 5 by Conviction

JH
Jones Hill Capital LP
15.36%
PA
Palo Alto Investors LP
5.92%
VP
Vestal Point Capital, LP
5.65%
SI
Sofinnova Investments, Inc.
1.68%
VG
Viking Global Investors LP
1.12%
View all 554 holding institutions

Quarterly Activity

Recent Activity

+$5.4B

Total Buy Value

$5.7B

Total Sell Value

New buy72
Trim166
Add214
Sold out71

286

Net Buyers

237

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

1

Filings (14d)

Data as of 2026-07-13
2026-07-13 (/A)

BioMarin Pharmaceutical Inc. filed an 8-K with the SEC on April 27, 2026. The filing includes audited financial statements of Amicus Therapeutics for fiscal years 2023 through 2025 and unaudited pro forma condensed combined financial information giving effect to the acquisition.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding BIOMARIN PHARMACEUTICAL INC (BMRN)?
Major stakeholders currently include BlackRock, Inc. ($1.1B), Dodge & Cox ($822.6M), Primecap Management Co/ca/ ($801.8M). Based on the latest 13F filings, there are a total of 554 tracked investment funds and institutions maintaining positions in BMRN.
What is the overall institutional sentiment toward BMRN recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $839.9M, driven by 286 managers accumulating shares while 237 reduced their exposure.
Which institutions have been selling or reducing their BMRN positions?
In the latest period, 166 funds trimmed their holdings, and 71 managers completely exited their positions. The aggregate reported sell value was $5.7B.
Are there any notable investors adding BMRN to their portfolios?
Yes, buying activity remains notable. 72 institutions opened new positions in {ticker}, and 214 existing holders added to their shares. The total reported buy value for the quarter amounted to $5.4B.

Related Stocks

Same Sector

Other stocks in the same GICS sector

JNJ

Johnson & Johnson

Institutions Holding

4,603

Total reported value

$438.8B

489 institutions currently hold both BMRN and this stock

View detail
LLY

Eli Lilly & Co

Institutions Holding

4,337

Total reported value

$730.5B

492 institutions currently hold both BMRN and this stock

View detail
ABBV

Abbvie INC

Institutions Holding

4,024

Total reported value

$283.9B

481 institutions currently hold both BMRN and this stock

View detail

Trending Institutional Adds

The most-added stocks by 13F institutions this quarter

MSFT

Microsoft CORP

Institutions Holding

6,150

Total reported value

$2.1T

3245 13F institutions increased their position this quarter

View detail
AMZN

Amazon.com INC

Institutions Holding

5,957

Total reported value

$1.5T

3028 13F institutions increased their position this quarter

View detail
NVDA

Nvidia CORP

Institutions Holding

5,764

Total reported value

$3.0T

2743 13F institutions increased their position this quarter

View detail